about
Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated conditionFeasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia.Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin.Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients.Treatment of patients with HCV infection with or without liver biopsy.Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients.Sequential treatment with lamivudine and alpha-interferon in anti-HBe-positive chronic hepatitis B patients: a pilot study.Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis.Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis.External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis.Unawareness of HBV infection among inpatients in a Southern Italian hospitalUnusual sonographic appearance of a haemorrhagic biliary cystProphylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis
P50
Q27490340-50268F9F-4DCA-472E-A3B1-8D7A67527827Q33414260-26B5057E-FB6D-42E0-9868-0614A09128F1Q33437717-7CE61344-FAFB-4C0C-9A10-BDE004AEF0A7Q37157057-47F448D5-7ABB-4083-A932-07348BFC766EQ40052609-5E329B05-5351-4E6C-862F-9DED174FEFF4Q40604604-1C017671-F7A9-40AC-9E91-F933622D8DD5Q42986651-21D23495-D613-416F-A315-9D0AC79866DFQ42987104-19C1A35F-4A1E-4ECD-88B0-3B383DBB5144Q42988394-E10FF5CF-F924-479C-B0B7-154BB6FFCA6FQ43033959-64AFDB36-1196-4130-8AC7-392FCC1AD893Q43253338-A0405483-9753-4BF7-B26D-A19C3ECCBEC0Q44181750-D587A4F2-9D3E-4D38-A6A6-D44AFAB33869Q45350934-F9090D3E-4FBF-48F4-BD84-0F0ED9E22009Q45371115-7AAA71C1-69B9-4515-BE78-E39A19F59BB7Q45423313-A05D1BFC-B57F-4F98-9C09-A610B95892D1Q46397593-28BFC167-21F2-4E46-A70E-4952590D702CQ57557330-42F94F07-4898-48E3-A77A-4E9168DAC1CBQ58945606-BD11C5B5-751C-4283-94DB-B56844E74A70Q60023343-D318A9B4-FE09-480D-9BE6-1143F975C8CC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelo Iacobellis
@ast
Angelo Iacobellis
@en
Angelo Iacobellis
@es
Angelo Iacobellis
@nl
Angelo Iacobellis
@sl
type
label
Angelo Iacobellis
@ast
Angelo Iacobellis
@en
Angelo Iacobellis
@es
Angelo Iacobellis
@nl
Angelo Iacobellis
@sl
prefLabel
Angelo Iacobellis
@ast
Angelo Iacobellis
@en
Angelo Iacobellis
@es
Angelo Iacobellis
@nl
Angelo Iacobellis
@sl
P1053
B-5133-2017
P106
P1153
6506246484
P21
P31
P3829
P496
0000-0003-0033-8506